<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860012</url>
  </required_header>
  <id_info>
    <org_study_id>Folic acid in Peds IBD</org_study_id>
    <nct_id>NCT03860012</nct_id>
  </id_info>
  <brief_title>Folic Acid in Pediatric Inflammatory Bowel Disease</brief_title>
  <official_title>Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Le Bonheur Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel disease often requires immunomodulators, such as methotrexate, to maintain
      disease remission. This medication is administered as one dose weekly. Methotrexate can cause
      folic acid deficiency, so the current recommendation is to give daily folic acid
      supplementation while on methotrexate. Standard of care is to administer folic acid
      supplements daily. Patient compliance with daily folic acid is often suboptimal. The
      rationale is that weekly folic acid supplementation is as efficacious as daily dosing, and
      less frequent dosing likely will help improve patient compliance. The optimal dosing schedule
      of folate supplementation in relation to methotrexate is not known and there are not many
      research studies that have studied changing dosing of folate supplementation. One particular
      research study examined the effect of different dosing of folic acid supplements in patients
      with rheumatoid arthritis taking methotrexate. The study showed that folic acid at two
      different doses per week (5 mg low dose vs 27.5 mg high dose) did not effect the efficacy of
      methotrexate therapy, and patients who were on either folic acid supplementation had lower
      toxicity scores compared to patients not on folic acid supplementation. This study shows that
      folic acid dosed once per week can be useful in preventing methotrexate toxicity for
      rheumatoid arthritis patients. There were no studies that could be found that have studied
      this correlation for pediatric inflammatory bowel disease. Based on this current study, once
      weekly dosing of folic acid in IBD patients on methotrexate has the potential to be as
      efficacious as daily dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy of once weekly supplemental folic acid
      dosing compared to daily dosing in patients with inflammatory bowel disease (IBD) on
      methotrexate.

      The study population is pediatric patients (ages 2-21) with inflammatory bowel disease on
      methotrexate who are receiving supplemental folic acid. The current standard of care is to
      administer folic acid supplements on a daily basis.

      This will be a prospective study involving pediatric IBD patients on methotrexate. Each
      patient's baseline folate levels and other routine labs at enrollment (time zero) will
      function as their control at the conclusion of the study.

      Doses will be standardized prior to study initiation. All patients will receive 800mcg of
      supplemental folic acid per week. IBD patients are typically evaluated and have lab draws
      every 6 months. For our study, labs will be obtained as routine labs (CBC, CMP) and a
      baseline folate level at the time of enrollment. Once these labs are obtained, patients with
      normal folate levels will qualify for inclusion in the study. They will be started on once
      weekly folate dosing. During the course of the study, if patients develop low folate levels,
      they will be removed from the study and placed back on daily doses of folate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will receive 800mcg of supplemental folic acid per week.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Folate level</measure>
    <time_frame>at 6 months</time_frame>
    <description>Evaluation of Folate level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Folate level</measure>
    <time_frame>at 12 months</time_frame>
    <description>Evaluation of Folate level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Folic Acid 800 mcg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.</description>
    <arm_group_label>Folic Acid 800 mcg once weekly</arm_group_label>
    <other_name>Folate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. inflammatory bowel disease

          2. on methotrexate at appropriate dosing

          3. normal folate levels at onset of study

          4. treatment with folic acid

          5. ages 2-21 years

        Exclusion Criteria:

          1. abnormal folate levels

          2. age &gt; 21 or less than 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsega A Temtem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsega A Temtem, MD</last_name>
    <phone>901-287-7337</phone>
    <email>ttemtem@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John R Whitworth, MD</last_name>
    <phone>901-287-7337</phone>
    <email>jwhitwor@uthsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsega A Temtem, MD</last_name>
      <phone>901-287-7489</phone>
      <email>ttemtem@uthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>John R Whitworth, MD</last_name>
      <phone>901-287-4017</phone>
      <email>jwhitwor@uthsc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bermejo F, Algaba A, Guerra I, Chaparro M, De-La-Poza G, Valer P, Piqueras B, Bermejo A, García-Alonso J, Pérez MJ, Gisbert JP. Should we monitor vitamin B12 and folate levels in Crohn's disease patients? Scand J Gastroenterol. 2013 Nov;48(11):1272-7. doi: 10.3109/00365521.2013.836752. Epub 2013 Sep 25.</citation>
    <PMID>24063425</PMID>
  </results_reference>
  <results_reference>
    <citation>Bermejo F, Algaba A, Guerra I, Gisbert JP. Response to letter: folate deficiency in Crohn's disease. Scand J Gastroenterol. 2014 Feb;49(2):255-6. doi: 10.3109/00365521.2013.869829. Epub 2013 Dec 16.</citation>
    <PMID>24328943</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhir V, Sandhu A, Kaur J, Pinto B, Kumar P, Kaur P, Gupta N, Sood A, Sharma A, Sharma S. Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015 Jun 11;17:156. doi: 10.1186/s13075-015-0668-4.</citation>
    <PMID>26063325</PMID>
  </results_reference>
  <results_reference>
    <citation>Dupont-Lucas C, Grandjean-Blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C. Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;23(2):298-303. doi: 10.1097/MIB.0000000000001014.</citation>
    <PMID>28107279</PMID>
  </results_reference>
  <results_reference>
    <citation>Heyman MB, Garnett EA, Shaikh N, Huen K, Jose FA, Harmatz P, Winter HS, Baldassano RN, Cohen SA, Gold BD, Kirschner BS, Ferry GD, Stege E, Holland N. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. Am J Clin Nutr. 2009 Feb;89(2):545-50. doi: 10.3945/ajcn.2008.26576. Epub 2008 Dec 30.</citation>
    <PMID>19116333</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaskel FJ, Bamgbola OF. Validation of a composite scoring scheme in the diagnosis of folate deficiency in a pediatric and adolescent dialysis cohort. J Ren Nutr. 2008 Sep;18(5):430-9. doi: 10.1053/j.jrn.2008.05.009.</citation>
    <PMID>18721738</PMID>
  </results_reference>
  <results_reference>
    <citation>Pan Y, Liu Y, Guo H, Jabir MS, Liu X, Cui W, Li D. Associations between Folate and Vitamin B12 Levels and Inflammatory Bowel Disease: A Meta-Analysis. Nutrients. 2017 Apr 13;9(4). pii: E382. doi: 10.3390/nu9040382. Review.</citation>
    <PMID>28406440</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JA, Shin HY. Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res. 2016 Mar;51(1):50-7. doi: 10.5045/br.2016.51.1.50. Epub 2016 Mar 25.</citation>
    <PMID>27104192</PMID>
  </results_reference>
  <results_reference>
    <citation>Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014 May;44(5):480-8. doi: 10.3109/00498254.2013.845705. Epub 2014 Feb 4. Review.</citation>
    <PMID>24494987</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methotrexate</keyword>
  <keyword>folic</keyword>
  <keyword>acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03860012/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

